RFA
BIO icon

Reilly Financial Advisors’s Bio-Rad Laboratories Class A BIO Stock Holding History

Reilly Financial Advisors’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$5K Buy
+6
New +$4.49K ﹤0.01% 822
2021
Q3 		– Sell
-6
Closed -$4K – 925
2021
Q2 		$4K Hold
6
– – ﹤0.01% 814
2021
Q1 		$3K Buy
+6
New +$3.55K ﹤0.01% 851

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Reilly Financial Advisors's BIO Position: Q4 2021 in Review

Reilly Financial Advisors opened a new position in Bio-Rad Laboratories Class A (BIO) in Q4 2021: 6 shares worth $5K. The stake represents ﹤0.01% of the portfolio and ranks #822 among its holdings. This is a return to the name: Reilly Financial Advisors previously reported a position in BIO as recently as Q2 2021.

Reilly Financial Advisors first reported a position in BIO in Q1 2021 and has held it in 3 quarters since. 534 funds tracked by Wall St. Rank hold BIO as of Q4 2021.

  • Reilly Financial Advisors held 6 shares of Bio-Rad Laboratories Class A worth $5K as of Q4 2021.
  • Bio-Rad Laboratories Class A was a new Reilly Financial Advisors position in Q4 2021.
  • Bio-Rad Laboratories Class A made up ﹤0.01% of Reilly Financial Advisors's portfolio in Q4 2021, its #822 holding.
  • Reilly Financial Advisors first reported a position in Bio-Rad Laboratories Class A in Q1 2021 and has held it in 3 quarters since.
  • 534 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2021.

Based on Reilly Financial Advisors's 13F filing for Q4 2021, filed 25 Jan 2022.